more

Gilead Sciences (GILD)

(Real Time Quote from BATS)

$74.14 USD

+0.84 (1.15%)

Updated Jul 18, 2024 10:28 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	24.15%
2	Buy	17.88%
3	Hold	9.47%
4	Sell	5.14%
5	Strong Sell	2.57%
S&P	500	11.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5 3

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth F Momentum C VGM

Industry Rank:

Top 28% (70 out of 250)

Industry: Medical - Biomedical and Genetics

View All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Liquidia (LQDA) PAH Drug Gets FDA's Complete Response Letter

by Zacks Equity Research Published on November 26,2020

The CRL issued to the NDA for Liquidia's (LQDA) LIQ861 stated that the FDA cannot approve the NDA in its present form

Biotech Stock Roundup: REGN's Cocktail Gets EUA, GILD & AMGN Provide Updates & More

by Zacks Equity Research Published on November 25,2020

Pipeline and regulatory updates take centerstage in the biotech sector as Regeneron (REGN) and Gilead Sciences (GILD), among others, provide updates on their pipeline candidates.

Regeneron's (REGN) Cocktail Gets EUA for COVID-19 by FDA

by Zacks Equity Research Published on November 24,2020

Regeneron's (REGN) antibody cocktail gets Emergency Use Authorization by the FDA for the treatment of COVID-19.

biotechs

The Zacks Analyst Blog Highlights: Gilead, Eli Lilly, Incyte and Pfizer

by Zacks Equity Research Published on November 24,2020

The Zacks Analyst Blog Highlights: Gilead, Eli Lilly, Incyte and Pfizer

pharmaceuticals

Lilly's (LLY) Coronavirus Treatment Gets Interim Nod in Canada

by Zacks Equity Research Published on November 24,2020

Lilly's (LLY) antibody drug bamlanivimab wins interim authorization from Health Canada to treat COVID-19. The company inks a genome editing research collaboration deal with Precision BioSciences.

pharmaceuticals

AstraZeneca's (AZN) sBLA for New Imfinzi Dosage Gets Approval

by Zacks Equity Research Published on November 24,2020

AstraZeneca's (AZN) Imfizni is now available in monthly, fixed-dose regimen as alternative to twice-monthly, weight-based regimen for all three approved indications.

pharmaceuticals

Gilead (GILD) Down on COVID-19 Drug Remdesivir Update

by Zacks Equity Research Published on November 20,2020

Gilead's (GILD) remdesivir should not be used for hospitalized COVID-19 patients, as per the WHO's conditional recommendation.

biotechs

Lilly/Incyte's Olumiant Gets FDA Emergency Nod for COVID-19

by Zacks Equity Research Published on November 20,2020

Lilly's (LLY) rheumatoid arthritis drug, Olumiant gets Emergency Use Authorization for treating hospitalized COVID-19 patients in combination with Gilead's Veklury.

pharmaceuticals

Gilead (GILD) Reports Positive Top-Line Data on HIV Candidate

by Zacks Equity Research Published on November 19,2020

Gilead (GILD) announces successful top-line results from a phase I/II study on its investigational, long-acting HIV-1 capsid inhibitor.

biotechs

Should Value Investors Choose Gilead Sciences (GILD) Stock?

by Zacks Equity Research Published on November 19,2020

Let's see if Gilead Sciences (GILD) stock is a good choice for value-oriented investors right now from multiple angles.

GILDPositive Net Change

What Awaits Pharma Giants in Last Lap of COVID-19 Vaccine Race?

by Ritujay Ghosh Published on November 19,2020

Pfizer, Inc. (PFE), BioNTech SE (BNTX), Eli Lilly and Company (LLY), AstraZeneca plc (AZN), Moderna, Inc. (MRNA) and Gilead Sciences, Inc. (GILD) are leading the race to come up with a vaccine for coronavirus.

Biotech Stock Roundup: MRNA's Progress With Coronavirus Vaccine, News From BMY, ALKS

by Zacks Equity Research Published on November 18,2020

Pipeline and regulatory updates take centerstage in the biotech sector as Moderna (MRNA) and Bristol Myers (BMY) among others provide updates.

Glaxo (GSK) Candidate Gets Breakthrough Tag for HIV Prevention

by Zacks Equity Research Published on November 18,2020

FDA grants breakthrough designation to Glaxo's (GSK) long-acting injectable cabotegravir to decrease the risk of HIV acquisition in at-risk populations.

Gilead (GILD), Novo Nordisk Post Upbeat Data From NASH Study

by Zacks Equity Research Published on November 16,2020

Gilead (GILD) and Novo Nordisk present favorable outcomes from a mid-stage study in NASH patients.

biotechs

3 Reasons to Bet on Healthcare ETFs

by Sanghamitra Saha Published on November 12,2020

The broader medical sector should be in the spotlight now on hopes of a coronavirus vaccine and the likelihood of a divided congress.

etfs
medical

Vaccine Hopes Rise as Pharma Giants Inch Closer Toward Success

by Ritujay Ghosh Published on November 11,2020

Stocks of Eli Lilly and Company (LLY), Pfizer, Inc. (PFE) and Moderna, Inc. (MRNA) have been in focus since the coronavirus outbreak as they have been the frontrunners in the vaccine race.

TEVA Posts In-Line Q3 Earnings, Lowers Sales View, Stock Down

by Zacks Equity Research Published on November 06,2020

TEVA's earnings match estimates while sales miss the same for third-quarter 2020. It lowers its previously issued sales guidance for 2020. Stock down.

pharmaceuticals

How Will Biotech ETFs React to These Q3 Earnings Release?

by Sweta Jaiswal, FRM Published on November 04,2020

Let's take a look at some ETFs with exposure to major players in the U.S. biotech industry, post their third-quarter earnings releases amid the coronavirus crisis.

Biotech Stock Roundup: Gilead, Amgen, Vertex and Alexion Report Q3 Earnings & More

by Zacks Equity Research Published on November 04,2020

Third-quarter earnings take centerstage in the biotech sector as Gilead (GILD), Amgen (AMGN) and others report results.

biotechs

Ligand (LGND) Q3 Earnings & Sales Fall Short of Estimates

by Zacks Equity Research Published on November 02,2020

Ligand (LGND) reports lower-than-expected third-quarter 2020 earnings and revenues. Outlook for 2020 & 2021 also are below expectations. Stock down.

biotechs

The Zacks Analyst Blog Highlights: Pinterest, Etsy, Gilead and Ford

by Zacks Equity Research Published on October 29,2020

The Zacks Analyst Blog Highlights: Pinterest, Etsy, Gilead and Ford

Gilead (GILD) Beats on Q3 Earnings & Sales, Lowers '20 View

by Zacks Equity Research Published on October 29,2020

Gilead (GILD) reports better-than-expected results for the third quarter owing to Veklury sales. However, the company lowers annual guidance.

Update on the COVID Vaccine Race

by John Blank Published on October 29,2020

A 2021 Macro Recovery is About This, Alone.

coronavirus